Daily Broadcaster

(Albany, US) September 29, 2026 – DelveInsight’s “Myasthenia Gravis – Pipeline Insight, 2026” report provides comprehensive insights about 28+ companies and 30+ pipeline drugs in the Myasthenia Gravis pipeline landscape. It covers the Myasthenia Gravis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myasthenia Gravis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Stay ahead in understanding the Myasthenia Gravis Treatment Landscape @ https://www.delveinsight.com/report-store/myasthenia-gravis-pipeline-insight

Key Takeaways from the Myasthenia Gravis Pipeline Report

• DelveInsight’s Myasthenia Gravis pipeline report depicts a robust space with 28+ active players working to develop 30+ pipeline therapies for Myasthenia Gravis treatment.

• The leading Myasthenia Gravis Companies include Dianthus Therapeutics, ImmunAbs Inc., Novartis AG, Bristol-Myers Squibb, Candid Therapeutics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Nanjing IASO Biotechnology Co., Ltd., Rallybio, Roivant Sciences (Immunovant Sciences GmbH), HanAll Biopharma, TG Therapeutics, Inc., Precision Biosciences, and others.

• Promising Myasthenia Gravis Pipeline Therapies such as Claseprubart (DNTH103), IM-101, Rapcabtagene autoleucel (YTB323), Zolacabtagene autoleucel, Cizutamig, SYS6020, Eque-cel (CT103A), RLYB116, Imeroprubart (IMVT-1402), Azercabtagene zapreleucel, and others.

• The companies which have their Myasthenia Gravis drug candidates in the most advanced stage, i.e. Phase III, include Dianthus Therapeutics and others.

Gain in-depth knowledge of key Myasthenia Gravis clinical trials, emerging drugs, and market opportunities @ Myasthenia Gravis Clinical Trials Assessment

Myasthenia Gravis Overview

Myasthenia gravis (MG) is a chronic autoimmune disorder of the neuromuscular junction characterized by fluctuating skeletal muscle weakness that worsens with activity and improves with rest. The disease most commonly affects the ocular, bulbar, respiratory, and limb muscles, and in most patients, autoantibodies directed against postsynaptic proteins impair neuromuscular transmission, resulting in fatigable muscle weakness.

MG develops in genetically susceptible individuals due to an autoimmune response against proteins at the neuromuscular junction, most commonly the nicotinic acetylcholine receptor (AChR), while other pathogenic antibodies target muscle-specific kinase (MuSK) or lipoprotein receptor-related protein 4 (LRP4). Approximately 10% of patients have an associated thymoma, and disease onset or exacerbation may be triggered by infections, surgery, immunization, medications, or other physiological stressors.

The pathogenesis of MG involves autoantibody-mediated disruption of neuromuscular transmission. In AChR-positive MG, IgG1 and IgG3 antibodies activate the complement cascade, leading to membrane attack complex (MAC) formation and destruction of the postsynaptic membrane; autoantibodies also block acetylcholine receptor function and accelerate receptor internalization, reducing the number of functional receptors available for neuromuscular signaling, and the resulting impairment of synaptic transmission causes muscle fatigability and weakness.

Diagnosis of MG is based on clinical presentation together with serological and electrophysiological testing. Detection of AChR, MuSK, or LRP4 antibodies supports the diagnosis, while repetitive nerve stimulation and single-fiber electromyography demonstrate impaired neuromuscular transmission; imaging of the thymus using CT or MRI is recommended to identify thymic hyperplasia or thymoma, and bedside tests along with assessment of response to acetylcholinesterase inhibitors may also aid diagnosis.

Treatment of MG focuses on improving neuromuscular transmission and suppressing the autoimmune response. Acetylcholinesterase inhibitors, particularly pyridostigmine, provide symptomatic relief, while corticosteroids and steroid-sparing immunosuppressants are used for long-term disease control. Rapidly acting therapies such as intravenous immunoglobulin (IVIG) or plasma exchange are indicated for myasthenic crisis or severe exacerbations, thymectomy is recommended in selected patients — especially those with thymoma — and targeted biologic therapies are increasingly used in patients with refractory disease.

Myasthenia Gravis Emerging Drugs Profile

• Claseprubart (DNTH103): Dianthus Therapeutics

Claseprubart is an investigational, clinical-stage, potent monoclonal antibody engineered to selectively target the classical complement pathway by inhibiting only the active form of the C1s protein, a clinically validated complement target. It is enhanced with YTE half-life extension technology designed to enable a more convenient subcutaneous, infrequently dosed, self-administered injection, and its selective inhibition of the classical pathway may lower patient risk of infection from encapsulated bacteria by preserving immune activity of the lectin and alternative pathways. Given the classical pathway’s significant role in disease pathology, claseprubart has the potential to be a best-in-class pipeline-in-a-product across a range of autoimmune disorders with high unmet need. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Myasthenia Gravis.

• IM-101: ImmunAbs Inc.

IM-101 is an investigational humanized anti-complement C5 monoclonal antibody developed for the treatment of generalized myasthenia gravis (gMG) and ocular myasthenia gravis (oMG). Administered by intravenous infusion, it is designed to selectively bind complement component C5 and inhibit its cleavage into C5a and C5b, preventing formation of the membrane attack complex (C5b-9) responsible for complement-mediated damage at the neuromuscular junction. By preserving acetylcholine receptor integrity and improving neuromuscular transmission, the therapy aims to reduce muscle weakness and disease symptoms. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Myasthenia Gravis.

• Rapcabtagene autoleucel (YTB323): Novartis AG

Rapcabtagene autoleucel is an investigational autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy developed for the treatment of generalized myasthenia gravis. Manufactured using the proprietary T-Charge™ platform, it is designed to preserve naïve and stem cell memory T cells, enabling rapid manufacturing while enhancing T-cell expansion and persistence; by targeting and eliminating CD19-expressing B cells, the therapy aims to reduce production of the pathogenic autoantibodies that drive myasthenia gravis. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Myasthenia Gravis.

• Zolacabtagene autoleucel: Bristol-Myers Squibb

Zolacabtagene autoleucel is an investigational autologous CD19-targeted NEX-T CAR T-cell therapy manufactured using the company’s NEX-T™ cell therapy platform, designed to enhance T-cell fitness, expansion, and persistence while enabling a streamlined manufacturing process. Following a single infusion, zola-cel selectively targets and eliminates CD19-expressing B cells, including autoreactive B cells that produce pathogenic autoantibodies implicated in MG, with the goal of achieving deep B-cell depletion, immune system reset, and durable disease remission. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Myasthenia Gravis.

The Myasthenia Gravis Pipeline Report Provides Insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Myasthenia Gravis, with aggregate therapies developed by each company.

• It assesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage development for Myasthenia Gravis treatment.

• Myasthenia Gravis Companies are involved in targeted therapeutics development, with respective active and inactive (dormant or discontinued) projects.

• Myasthenia Gravis drugs under development are categorized based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, mechanism of action, and molecule type.

• Detailed analysis of collaborations (company-company and company-academia), licensing agreements, mergers and acquisitions, and funding for future advancement of the Myasthenia Gravis market.

Uncover critical updates on therapeutic innovations and their potential impact on patients @ Myasthenia Gravis Unmet Needs

Myasthenia Gravis Companies

Dianthus Therapeutics, ImmunAbs Inc., Novartis AG, Bristol-Myers Squibb, Candid Therapeutics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Nanjing IASO Biotechnology Co., Ltd., Rallybio, Roivant Sciences (Immunovant Sciences GmbH), HanAll Biopharma, TG Therapeutics, Inc., Precision Biosciences, and others.

Myasthenia Gravis pipeline report provides the therapeutic assessment of the pipeline drugs by Route of Administration. Products have been categorized under various ROAs such as:

• Intra-articular

• Intraocular

• Intrathecal

• Intravenous

• Ophthalmic

• Oral

• Parenteral

• Subcutaneous

• Topical

• Transdermal

Myasthenia Gravis Products have been categorized under various Molecule types such as:

• Oligonucleotide

• Peptide

• Small molecule

Transform your understanding of the Myasthenia Gravis Pipeline! @ Myasthenia Gravis Market Drivers and Barriers, and Future Perspectives

Scope of the Myasthenia Gravis Pipeline Report

• Coverage- Global

• Myasthenia Gravis Companies- Dianthus Therapeutics, ImmunAbs Inc., Novartis AG, Bristol-Myers Squibb, Candid Therapeutics, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Nanjing IASO Biotechnology Co., Ltd., Rallybio, Roivant Sciences (Immunovant Sciences GmbH), HanAll Biopharma, TG Therapeutics, Inc., Precision Biosciences and others.

• Myasthenia Gravis Pipeline Therapies- Claseprubart (DNTH103), IM-101, Zolacabtagene autoleucel, Rapcabtagene autoleucel (YTB323), Cizutamig, SYS6020, Eque-cel (CT103A), RLYB116, Imeroprubart (IMVT-1402), Azercabtagene zapreleucel and others.

• Myasthenia Gravis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination

• Myasthenia Gravis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Access the Full Myasthenia Gravis Pipeline Analysis Today! @ Myasthenia Gravis Drugs and Companies

Table of Contents

• Introduction

• Executive Summary

• Myasthenia Gravis: Overview

• Pipeline Therapeutics

• Comparative Analysis

• Therapeutic Assessment

• Myasthenia Gravis: DelveInsight’s Analytical Perspective

• Late Stage Products (Phase III)

• Mid Stage Products (Phase II)

• Early Stage Products (Phase I)

• Preclinical and Discovery Stage Products

• Inactive Products

• Myasthenia Gravis Key Companies

• Myasthenia Gravis Key Products

• Myasthenia Gravis: Unmet Needs

• Myasthenia Gravis: Market Drivers and Barriers

• Myasthenia Gravis: Future Perspectives and Conclusion

• Myasthenia Gravis Analyst Views

• Myasthenia Gravis Key Companies

• Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kanishk Kumar
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/myasthenia-gravis-pipeline-insight